Differences among GP IIb/IIIa inhibitors: Different clinical benefits in non-ST-segment elevation acute coronary syndrome percutaneous coronary intervention patients

European Heart Journal, Supplement

Volumn 9, Issue A, 2007, Pages

  Antoniucci, David ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Acute coronary syndromes; Glycoprotein IIb IIIa inhibitors

Indexed keywords

ABCIXIMAB; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN IIB IIIA RECEPTOR; HEPARIN; HIRULOG; RECEPTOR SUBUNIT; TIROFIBAN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; BLEEDING; CELL ADHESION; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENDOTHELIUM CELL; HEART INFARCTION; HUMAN; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ADHERENCE INHIBITION; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; ST SEGMENT ELEVATION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 33847158725     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sul069     Document Type: Review

References (37)

1. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961 .
2. EPILOG Investigators. Platelet glycoprotein IIb/IIIa blockade with abciximab with low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
3. EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
4. The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndrome. N Engl J Med 1998;339:436-443.
5. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-1453.
6. CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-1435.
7. O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, Strodey J, Tcheng JE. Platelet glyprotein integrin blockade with eptifibatide in coronary stent implantation. The ESPRIT trial: a randomised controlled trial. JAMA 2001;285:2468-2473.
8. Linkoff AM, Califf RM, Topol EJ. Platelet glycoprotein blockade in coronary artery disease. J Am Coll Cardiol 2000;35:1103-1115.
9. Linkoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997;30:140-150.
10. Topol EJ, Mark DB, Linkoff AM, Cohen F, Buton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot JF, Andrson KM, Califf RM. Enhanced survival with platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stent implantation: one-year outcomes and health care economic implications from a multicenter randomised trial. Lancet 1999;354:2019-2024.
11. Topol EJ, Lincoff AM, Kereiakes DJ, Kleiman NS, Cohen EA, Ferguson JJ, Tcheng JE, Sapp S, Califf RM. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002;113:1-6.
12. Anderson KM, Califf RM, Stone GW, Nemann F-J, Montalescot G, Miller DP, Ferguson JJ, Willerson JT, Weisman HF, Topol EJ. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001;37:2059-2065.
13. TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischaemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-1894.
14. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and avβ3 integrins. Circulation 1998;98:1085-1091.
15. Neumann F-J, Zohlnhöfer D, Fakhoury L, Ott I, Gawaz M, Schömig A. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999;34:1420-1426.
16. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997;17:528-535.
17. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alpha-IIb beta-3 and stimulated by platelet activating factor. J Clin Invest 1997;100:2085-2093.
18. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-424.
19. Biasucci LM, Liuzzo G, Fantuzzi G, Caliguri G, Rebuzzi AG, Ginetti F, Dinarello, Maseri A. Increasing levels of interleuken (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999;99:2079-2084.
20. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin C. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000;343:1139-1147.
21. Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, Gioffré PA. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary stent implantation. Am J Cardiol 2000;85:92-95.
22. Lincoff AM, Keriakes DJ, Mascelli MA, Deckelbaun LI, Barnathan ES, Patel KK, Frederik B, Nakada MT, Topol EJ. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001;104:163-167.
23. Neumann F-J, Blasini R, Schmitt C, Alt E, Dirshinger J, Gawaz M, Kastrati A, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary artery stents in acute myocardial infarction. Circulation 1998;98:2695-2701.
24. Gibson MC, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, Lui HH, Bulle T, Lakkis N, Korach R, Cohen DJ, Fish P, McCabe CH, Braunwald E. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, inflammation among antiplatelet and antithrobotic agents. The PROTECT-TIMI 30 trial. J Am Coll Cardiol 2006;47:2364-2373.
25. Gibson CM, Cohen DJ, Cohen EA, Lui HK, Murphy SA, Marble SJ, Kitt M, Lorenz T, Tcheng JE. Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy) Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Am J Cardiol 2001;87:1293-1295.
26. Welt FG, Rogers SD, Zhang X, Ehler R, Chen Z, Nannizzi-Alajimo L, Phillips DR, Simon DI. Glycoprotein IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Catheter Cardiovasc Intervent 2004;61:185-189.
27. Furman MI, Krueger LA, Linden MD, Fox MC, Ball SP, Barnard MR, Frelingen AL, Michelson AD. GPIIb-IIIa antagonists reduce thromboin-flammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost 2005;3:312-320.
28. Mukherjee D, Topol EJ, Bertrand ME, Kristensen SD, Herman HC, Neumann FJ, Yakubov SJ, Bassabd JP, McClure RR, Stone GW, Ardissino D, Moliterno DJ. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1 year follow-up. Eur Heart J 2005;26:2523-2527.
29. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW,Moliterno DJ, Califf RM, White HD, Kleiman NS, Theroux P, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001;104:2767-2771.
30. Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999;354:1757-1762.
31. Antman EM, Tanasijevic MJ, Thompson B, Schractman M, McCabe CH, Cannon CP, Fisher GA, Fung AY, Thomson C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-1349.
32. Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. Circulation 1996;93:1651-1657.
33. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O'Hanesian MA, Wagner GS, Kleiman NS, Harrel FE, Califf RM, Topol EJ. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 1996;335:1333-1341.
34. Hamm CW, Heeschen C, Goldmann B, Vahanien A, Adgey J, Miguel CH, Rutsch W, Bergen J, Kootstra J, Simoons ML. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1623-1629.
35. Kastrati A, Mehilli J, Neumann F-J, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Poche J, Slyforth M, Schuhlen H, Dirshinger J, Berger PB, Schomig A. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pre-treatment. JAMA 2006;295:1531-1538.
36. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarenbock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen FA, Betriu A, Desmet W, Rutsch W, Wilcox RG, De Feyter PG, Vahanian A, Topol EJ. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs. heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696- 703.
37. Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Fest F, Lansky AJ, Lincoff AM, Mehran R, Moses JW, Ohman M, White HD. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J 2004;48:764-775.